Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early-stage follicular lymphoma radiotherapy plus anti-CD20 antibody trial
2021-000362-15Phase 3Active
- Sponsor
- Heidelberg University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing Standard-dose radiotherapy plus rituximab with Low-dose radiotherapy plus obinutuzumab (2 arms). Primary endpoint: Morphologic complete response at week 18. Started Dec 2021; status: active.
02
Drugs
obinutuzumabrituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2021-000362-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000362-15.